Advertisement

Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Organisation › Details

GeNeuro S.A. (Euronext Paris: GNRO)

GeNeuro was created in 2006 by Eclosion, the Geneva life sciences accelerator, as a spin-off of Institut Mérieux of France. It develops first-in-class therapies against diseases associated with the expression of pathogenic proteins of human endogenous retroviral origin (HERV). GeNeuro’s lead product, GNbAC1, is a therapeutic antibody that targets MSRV-Env, a protein expressed in Multiple Sclerosis (MS) lesions from an early stage, which has been shown to be both pro-inflammatory and an inhibitor of remyelination, the two major drivers of MS progression. The Multiple Sclerosis associated retrovirus (MSRV) is normally latent in the genome of individuals, but it can be re-activated by viral infections and other co-factors to express a pathogenic protein, MSRV-Env. MSRV-Env provides a missing link between the observation that viral infections are associated with the onset of the disease and expression of the pathogenic factor (the MSRV-Env protein), which can then explain the inflammatory and demyelinating characteristics of MS. By targeting a potential key factor present in all types of MS that fuels both inflammation and neurodegeneration, GeNeuro aims to bring to patients a safe, long-term treatment with the potential to reduce or stop progression of the disease. As the first drug intended to address a potential causal factor of the disease, it may radically change the way MS patients are treated. *

 

Period Start 2006-01-01 established
Products Industry CNS drug
  Industry 2 diagnostics (medical/biological)
Persons Person Martin-Garcia, Jesús (Eclosion 201207 General Partner + Founder + GeNeuro 201512 CEO)
  Person 2 Curtin, Francois (Geneuro 201207 CEO)
     
Region Region Plan-les-Ouates GE
  Country Switzerland
  Street 18 Chemin des Aulx
  City 1228 Plan-les-Ouates GE
  Tel +41-22-794-5085
    Address record changed: 2013-11-10
     
Basic data Employees B: 11 to 50 (2019-11-25)
     
    * Document for �About Section�: Servier. (12/18/15). "Press Release: GeNeuro Announces the Launch of Phase IIb Proof-of-Concept Study with GNbAC1 in Multiple Sclerosis and Servier Equity Investment". Geneva & Suresnes.
     
   
Record changed: 2020-02-10

Advertisement

Picture [iito] Männer Ballett 650x80px

More documents for GeNeuro S.A. (Euronext Paris: GNRO)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81




» top